MDxHealth (MDXH) Stock Price, News & Analysis

Company Overview

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx. ConfirmMDx is an epigenetic assay performed on prostate biopsy tissue to identify men at risk of harboring occult high-grade prostate cancer following a negative biopsy result. SelectMDx is a non-invasive urine test designed to assess the likelihood of clinically significant prostate cancer before an initial biopsy, helping to reduce unnecessary procedures. Both tests are performed in MDxHealth’s CLIA-certified laboratory in the United States and its ISO-certified laboratory in Europe, and are used by urologists worldwide to guide biopsy and treatment decisions.

Founded in 2003, MDxHealth has established a global footprint, serving patients and healthcare providers across North America, Europe and select international markets through direct lab services and strategic partnerships. The company is led by President and CEO Caroline Palm, who brings extensive experience in molecular diagnostics and life sciences. MDxHealth is publicly traded on the Nasdaq under the ticker symbol MDXH.

Key Stats

• Today's Range: $0.80 to $0.84
• 50-Day Range: $0.80 to $3.37
• 52-Week Range: $0.68 to $5.33
• Volume: 914,639 shs
• Average Volume: 1.06 million shs
• Market Capitalization: $39.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.63
• Consensus Rating: Moderate Buy

MDxHealth Stock Analysis - MarketRank™

MDxHealth scored higher than 51% of companies evaluated by MarketBeat, and ranked 490th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MDxHealth has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

MDxHealth has a consensus price target of $4.63, representing about 478.1% upside from its current price of $0.80.

Amount of Analyst Coverage

MDxHealth has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MDxHealth are expected to grow in the coming year, from ($0.60) to ($0.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MDxHealth is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MDxHealth is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of MDxHealth has been sold short.

Short Interest Ratio / Days to Cover

MDxHealth has a short interest ratio ("days to cover") of 0.41, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MDxHealth has recently increased by 171.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MDxHealth does not currently pay a dividend.

Dividend Growth

MDxHealth does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added MDxHealth to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MDxHealth insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of MDxHealth is held by insiders.

Percentage Held by Institutions

MDxHealth has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 5/25/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MDXH
• CIK: 1872529
• Web: mdxhealth.com
• Phone: 324-364-2070
• Fax: 32042597875
• Employees: 300
• Year Founded: 2003

Price Target and Rating

• Average Price Target for MDxHealth: $4.63
• High Price Target: $8.00
• Low Price Target: $1.50
• Potential Upside/Downside: +478.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.52 million
• Net Margins: -29.90%
• Pretax Margin: -32.79%
• Return on Equity: -1,078.01%
• Return on Assets: -22.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.63
• Quick Ratio: 1.46

Sales & Book Value

• Annual Sales: $110.97 million
• Price / Sales: 0.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.41) per share
• Price / Book: -1.95

Miscellaneous

• Outstanding Shares: 49,497,000
• Free Float: 48,656,000
• Market Cap: $39.60 million
• Optionable: Not Optionable
• Beta: 1.60